David Sommerhalder is an Oncology physician. OpenAlex indexes 107 publications with 731 citations (h-index 12); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
- Cardiovascular Safety Study of Tipifarnib in Patients With Advanced Solid Malignancies
Sponsor: Kura Oncology, Inc.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
55 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ExelixisProgram year2025283 paymentsResearch$638,832openpaymentsdata.cms.gov ↗
- AbbVieProgram year2025184 paymentsResearch$387,447openpaymentsdata.cms.gov ↗
- Day One BiopharmaceuticalsProgram year2025128 paymentsResearch$343,527openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Blood & clotting
65.1%Parenteral Iron Replacement64.8%Iron sucrose100%Part B, office-administered≥15 patientsFactor Xa inhibitor0.3%Eliquis63%Xarelto37%Part D<11 patientsMusculoskeletal
25.9%RANK Ligand Inhibitor25.9%Denosumab100%Part B, office-administered≥12 patientsMetabolism & gastrointestinal
5.1%Serotonin-3 Receptor Antagonist4.6%Granisetron hydrochloride96%Granisetron Hcl4%Part D + Part B<11 patientsCorticosteroid0.3%Prednisone100%Part D≥13 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Daraxonrasib in Previously Treated Advanced RAS -Mutated Pancreatic Cancer
New England Journal of Medicine
2026 - Daraxonrasib for Previously Treated RAS -Mutant Non–Small-Cell Lung Cancer
New England Journal of Medicine
2026
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”